SNGX — Soligenix, Inc.
Is SNGX overbought or oversold? Here is the current MarketMoodz read.
Soligenix, Inc. (SNGX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.29. The rating moved from Strong Oversold to Oversold on November 13, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$0.29
- Last changeMoved from Strong Oversold to Oversold on November 13, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Analysis for Soligenix, Inc. (SNGX): The company exhibits characteristics of a small, speculative biotech with limited public financial detail and elevated financing vulnerability. Current market conditions favor larger, defensive pharmaceutical names, reducing appetite for micro‑cap clinical stories. Key downside drivers include likely near‑term funding needs, potential dilution, and binary clinical/regulatory risk; upside would require a material positive clinical readout, a strategic partnership, or successful non‑dilutive financing. Liquidity constraints amplify downside risk and make short‑term price movements sensitive to news or financing events. Given the absence of recent EDGAR or social‑sentiment data, near‑term outlook is driven primarily by capital markets dynamics and sector flows rather than visible fundamental improvements.
Key factors
- Micro‑cap biotech with limited publicly available financial disclosures and no recent EDGAR filing analysis provided
- High cash burn profile typical of early/clinical‑stage biotechs, implying funding needs and dilution risk absent partnerships or non‑dilutive financing
- Sector flows favor large‑cap pharma and defensive names, reducing investor appetite for small speculative healthcare names
- Convertible‑debt and financing market dynamics in the sector increase the likelihood of dilutive financings for smaller issuers
- Low liquidity and thin trading can amplify downside moves on negative news or financing announcements
- Potential binary upside from clinical or regulatory catalysts exists but timing and probability are highly uncertain
Risks
- Need for near‑term financing leading to significant equity dilution or expensive convertible debt
- Clinical trial failures or unfavorable regulatory outcomes for pipeline assets
- Limited transparency due to lack of recent filings or detailed public financial data
- Adverse sector rotation away from small‑cap biotechs into large‑cap pharma and defensive healthcare
- Extreme share price volatility due to low float and low average daily volume
- Counterparty/partnering risk if collaboration agreements are required to commercialize programs
- Broader market selloffs or tightening of credit conditions that reduce access to capital markets
See today's live rating, score and targets
Members see the live hourly rating for SNGX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.